X-GEN Congress and Expo Features GenomeQuest Panel Session on 
Whole-Genome Diagnostics and Significance to Research

Insight to Research Community from Experts in Sequencing, Pharma, IT, Diagnostic, and Payers

Title: Whole Genome Sequencing Applied to Clinical Diagnostics — the Significance to the Research Community

Location: X-Gen Congress and Expo, Hilton San Diego Resort, San Diego, CA

When: Friday, March 18, 2011 from 11:00am-11:50 am PST

Background:
Whole-genome sequencing applied to diagnostics holds great promise for health care. Globally, the world spends about $5T on health care and about 65% of therapy decisions are based on the results of diagnostics tests.

With the precipitous fall in the cost of sequencing, whole-genome sequencing may soon become practical – even common – for reporting on patient susceptibility, diagnosis, and treatment of genetic disorders. Benefits of this advance to medical professionals and patients include: higher precision, ability to detect complex/multi-gene conditions, far lower long-term costs for patients, economies of scale for instrument manufacturers, higher quality/repeatability for laboratories, and faster delivery/approval of research discoveries.

Included in this panel discussion is a demonstration of a newly released capability to analyze/report on a patient’s disease susceptibility, diagnosis, and treatment on over 2000 disorders from a single whole-genome sequence.

  • Topics and questions addressed by this panel:

    • What research and technological developments will help drive this advance?
    • How can we better integrate research and clinical efforts/data to accelerate “translation”?
    • What does this mean for researchers and their organizations?
    • What are the top research bottlenecks/concerns and what can be done to address them?
  • Panel Participants:

    • Richard Resnick, CEO, GenomeQuest, Inc. (Moderator)
    • Eliot Shearer, University of Iowa Carver College of Medicine
    • Francois Ferre, PhD, CEO and President, AltheaDx
    • Harry Glorikian, CEO, Scientia Advisors
    • Michael Moradian, PhD, Molecular Diagnostics, Kaiser Permanente
    • Greg Heath, PhD, SVP and GM, Diagnostics, Illumina
    • Eric Glazer, Managing Director, NGS Leaders (Host)